{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.55","upperLimit":"0.73","value":"0.64"},{"groupId":"OG001","lowerLimit":"0.90","upperLimit":"0.98","value":"0.94"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"description":"Proportion of patients experiencing at least one Grade 3 or higher toxicity.","dispersionType":"95% Confidence Interval","groups":[{"description":"Randomized to Regimen A - RA Only","id":"OG000","title":"Regimen A"},{"description":"Patients that received RA + Immunotherapy before halting of randomization","id":"OG001","title":"Regimen B"}],"paramType":"NUMBER","populationDescription":"Eligible patients enrolled prior to halting of randomization.","reportingStatus":"POSTED","timeFrame":"From enrollment to follow-up","title":"Incidence of Toxicities Assessed Using Common Terminology Criteria for Adverse Events Version 4.0","type":"SECONDARY","unitOfMeasure":"Proportion"}